 |
| Daewoong Pharmaceutical headquarters in Gangnam-gu, Seoul. © News1 |
The botulinum toxin ingredient formulation’Nabota’ (US export name Jubo), developed by Daewoong Pharmaceutical, prescribed for skin wrinkle improvement, will resume sales in the US.
Daewoong Pharmaceutical announced that an emergency motion to interim stay application for suspension of execution of an import ban order that had been filed with the US Federal Circuit Court of Appeals (CAFC) earlier on the 15th (US time) was cited. It was quickly quoted three days after applying for provisional injunction on the 12th.
As a result, Nabota, which received a 21-month import ban from the US International Trade Commission (ITC) in December last year, can resume sales without a gap.
ITC determined that Daewoong Pharmaceutical and Ebolus, a US Nabota sales company, infringed on the manufacturing process technology of’Meditoxin’, a botulinum toxin, a domestic company, and took Nabota’s 21-month import ban.
The deposit amount is decided upon by an appeal trial or the final decision of the Supreme Court. If Ebolus wins, the entire deposit will be returned.
The emergency provisional injunction is effective until the court of appeals decides to cite this provisional injunction. This provisional injunction completed the application on the 12th so that’Goldstein and Russell’, a law firm representing Daewoong Pharmaceutical, can be cited without deposit for the smooth sale of Nabota.
A representative from Daewoong Pharmaceutical said, “We welcome Evolus to continue its business even during the appeal period with CAFC’s rapid decision.” Said.